Protego Biopharma

About Protego Biopharma

Protego Biopharma is dedicated to the discovery and development of first-in-class small molecule therapeutics aimed at reprogramming protein folding to treat various diseases, particularly protein misfolding diseases. Their mission is to accelerate therapies for conditions such as myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and degenerative diseases using innovative approaches like pharmacological chaperones.

Products & Services

Pharmacological Chaperones:Small molecule therapeutics designed to bind and modulate target protein stability to restore healthy-state structure and function for treating protein misfolding diseases.

Pipeline Programs:Advancing key programs targeting diseases with high unmet medical needs related to protein misfolding.

Specialties

Protein Misfolding Diseases Pharmacological Chaperones Small Molecule Therapeutics Biomarker Discovery Precision Medicine Translational Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 130000000 MR: - FA: $130 million FAN: 130000000	D: 2025-12-01 FD: 2025-12-01	10 investors

Series B Latest

2025-12-01

$130.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeffrey W. Kelly

Professor, H. Lutcher Brown Professor of Chemistry

R

Richard Labaudinière

Co-Founder and Former Chief Executive Officer

B

Brent Warner

Chief Executive Officer

LinkedIn (Pro only)

M

Mike Petrassi

Chief Scientific Officer

C

Chris Weyrer, M.D., Ph.D.

Acting Chief Business Officer

D

Deborah Tower

VP of Finance

View 15 more team members with Pro

Unlock Full Team Directory

Recent News